Patents by Inventor Aaron Balog

Aaron Balog has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • UBIQUITIN SPECIFIC PROCESSING PROTEASE 1 (USP1) COMPOUNDS
    Publication number: 20250145590
    Abstract: Compounds having the following formula I or a stereoisomer or pharmaceutically-acceptable salt thereof, where all substituents are as defined herein, are inhibitors of USP1 useful for treating diseases including, among others, treating proliferative, metabolic, allergic, autoimmune and inflammatory diseases.
    Type: Application
    Filed: October 30, 2024
    Publication date: May 8, 2025
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: KHEHYONG NGU, ROBERT J. CHERNEY, YANTING HUANG, WEI MENG, MURALI T.G. DHAR, LI-QIANG SUN, ZHIZHEN BARBARA ZHENG, JAMES AARON BALOG
  • Galectin-3 inhibitors
    Patent number: 12291522
    Abstract: The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: May 6, 2025
    Assignee: Bristol-Myers Squibb Company
    Inventors: Chunjian Liu, Wei Wang, Bruce A. Ellsworth, James Aaron Balog, Alicia Regueiro-Ren
  • SUBSTITUTED PHENYL OXAZOLONE COMPOUNDS
    Publication number: 20250129061
    Abstract: Disclosed are compounds of Formula (I): or stereoisomers, tautomers, or salts thereof, wherein each R is independently H or D. Also disclosed are methods of using such compounds to decrease the levels of IKZF1-4 proteins, and pharmaceutical compositions comprising the compound. The compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: December 4, 2024
    Publication date: April 24, 2025
    Applicant: Bristol-Myers Squibb Company
    Inventors: Lan-Ying QIN, Zheming RUAN, Ashok Vinayak PURANDARE, Emily Charlotte CHERNEY, James Aaron BALOG, Arvind MATHUR, Samuel J. BONACORSI
  • Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
    Patent number: 12145927
    Abstract: The present invention provides compounds of formula (I) wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: November 19, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Steven P. Seitz, Jay A. Markwalder, David K. Williams, Weifang Shan, Susheel Jethanand Nara, Saumya Roy, Srinivas Cheruku, Nagalakshmi Pulicharla
  • PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS
    Publication number: 20240376082
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein R1, R2, R4, R6, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: June 25, 2024
    Publication date: November 14, 2024
    Inventors: Yan Chen, Godwin Kwame Kumi, Audris Huang, Satheesh Kesavan Nair, Bharat Dinkar Shimpukade, Suresh Babu Vishwa Krishna Penmetsa, James Aaron Balog
  • Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
    Patent number: 12059420
    Abstract: The present invention provides compounds of formula (I): wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: August 13, 2024
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Jay A. Markwalder, Weifang Shan, David K. Williams, Susheel Jethanand Nara, Saumya Roy, Soodamani Thangavel, Srinivas Cheruku, Ramesh Kumar Sistla
  • Immunoregulatory agents
    Patent number: 11932601
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Grant
    Filed: December 16, 2021
    Date of Patent: March 19, 2024
    Assignee: Flexus Biosciences, Inc.
    Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Weiwei Guo
  • GALECTIN-3 INHIBITORS
    Publication number: 20230303538
    Abstract: The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions.
    Type: Application
    Filed: May 27, 2021
    Publication date: September 28, 2023
    Inventors: CHUNJIAN LIU, Wei Wang, Bruce A. Ellsworth, James Aaron Balog, Alicia Regueiro-Ren
  • PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS
    Publication number: 20230303527
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein R1, R2, R4, R6, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: June 8, 2023
    Publication date: September 28, 2023
    Inventors: Yan Chen, Godwin Kwame Kumi, Audris Huang, Satheesh Kesavan Nair, Bharat Dinkar Shimpukade, Suresh Babu Vishwa Krishna Penmetsa, James Aaron Balog
  • Pyridinyl substituted oxoisoindoline compounds
    Patent number: 11718601
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein R1, R2, R4, R6, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Grant
    Filed: April 5, 2022
    Date of Patent: August 8, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yan Chen, Godwin Kwame Kumi, Audris Huang, Satheesh Kesavan Nair, Bharat Dinkar Shimpukade, Suresh Babu Vishwa Krishna Penmetsa, James Aaron Balog
  • Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
    Patent number: 11649212
    Abstract: The present invention provides compounds of formula (I), formula (II) or formula (III), wherein all of the variables are as defined herein. These compounds are inhibitors of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: May 16, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Emily Charlotte Cherney, Weifang Shan, David K. Williams, Liping Zhang
  • Compounds useful as inhibitors of helios protein
    Patent number: 11548870
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: Z is CR6R6 or C?O; Ring A is: and R1, R2, R3, R4, R5, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Grant
    Filed: November 18, 2020
    Date of Patent: January 10, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Andrew P. Degnan, Godwin Kwame Kumi, Audris Huang, James Aaron Balog, Ashok Vinayak Purandare, Weifang Shan, Guo Li
  • PYRIDINYL SUBSTITUTED OXOISOINDOLINE COMPOUNDS
    Publication number: 20220324840
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein R1, R2, R4, R6, m, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: April 5, 2022
    Publication date: October 13, 2022
    Inventors: Yan Chen, Godwin Kwame Kumi, Audris Huang, Satheesh Kesavan Nair, Bharat Dinkar Shimpukade, Suresh Babu Vishwa Krishna Penmetsa, James Aaron Balog
  • RADIOLIGANDS FOR IMAGING THE ID01 ENZYME
    Publication number: 20220305144
    Abstract: The present invention relates to radiolabeled IDO1 inhibitors or pharmaceutically acceptable salts thereof which are useful for the quantitative imaging of IDO enzymes in mammals.
    Type: Application
    Filed: April 18, 2022
    Publication date: September 29, 2022
    Inventors: David J. Donnelly, Erin Lee Cole, Richard Charles Burrell, Wesley A. Turley, Alban J. Allentoff, Michael Arthur Wallace, James Aaron Balog, Audris Huang, Mette Skinbjerg
  • Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
    Patent number: 11447449
    Abstract: The present invention provides a compound of formula (II): an inhibitor of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmune diseases. Its prodrugs are disclosed.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: September 20, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Steven P. Seitz, David K. Williams, Murugaiah Andappan Murugaiah Subbaiah
  • IMMUNOREGULATORY AGENTS
    Publication number: 20220274926
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Application
    Filed: December 16, 2021
    Publication date: September 1, 2022
    Inventors: Hilary Plake BECK, Juan Carlos JAEN, Maksim OSIPOV, Jay Patrick POWERS, Maureen Kay REILLY, Hunter Paul SHUNATONA, James Ross WALKER, Mikhail ZIBINSKY, James Aaron BALOG, David K. WILLIAMS, Weiwei GUO
  • Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
    Patent number: 11351164
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compound and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: June 7, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Liping Zhang, Emily Charlotte Cherney, James Aaron Balog, Xiao Zhu
  • Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
    Patent number: 11337970
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: May 24, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: Emily Charlotte Cherney, Weifang Shan, Liping Zhang, Susheel Jethanand Nara, Audris Huang, James Aaron Balog
  • Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
    Patent number: 11253525
    Abstract: There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the disclosure.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: February 22, 2022
    Assignee: Bristol-Myers Squibb Company
    Inventors: James Aaron Balog, Steven P. Seitz, Susheel Jethanand Nara, Saumya Roy, Srinivasan Thangathirupathy, Soodamani Thangavel, Srinivas Cheruku
  • Immunoregulatory agents
    Patent number: 11242319
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Grant
    Filed: November 5, 2015
    Date of Patent: February 8, 2022
    Assignee: Flexus Biosciences, Inc.
    Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Weiwei Guo